Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Eli Lilly and Company and Walmart have announced a partnership to offer Zepbound single-dose vials at Walmart pharmacies. The ...

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...

Lilly now says it expects non-GAAP earnings from $23 to $23.70 a share this year, up from $21.75 to $23. The new guidance is ...

Pharma giant Eli Lilly tapped Walmart to offer in-store pickups of Zepbound vials, marking the first retail collaboration for ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

Drug company Eli Lilly and NVIDIA announced a new partnership to build a supercomputer for drug research. Drug manufacturer ...

The drugmaker hopes an Nvidia-chip powered supercomputer will help it find new drugs and accelerate lengthy R&D timelines.

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...